News about "Boehringer Ingelheim"

IQVIA and Boehringer Ingelheim Partner on Global Commercial Data Transformation

The long-term strategic collaboration aims to modernise Boehringer Ingelheim’s global commercial data foundation, enabling scalable, advanced analytics across therapeutic areas and regions using IQVIA’s industry-leading data model.

Boehringer Ingelheim | 31/01/2026 | By News Bureau

Boehringer Ingelheim's Apecotrep Cuts Proteinuria by 40 percent in Phase II Trial for Rare Kidney Disease FSGS

Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.

Boehringer Ingelheim | 29/01/2026 | By News Bureau

Boehringer and Simcere Partner on Dual-Target IBD Antibody

Boehringer Ingelheim has signed a licence and collaboration deal with Simcere to develop a novel TL1A/IL23p19 bispecific antibody for inflammatory bowel disease, gaining global rights outside greater China, with Simcere eligible for up to €1.058 billion in payments.

Boehringer Ingelheim | 29/01/2026 | By News Bureau

Boehringer Ingelheim Begins Phase IIa Trial of BI 765423 in IPF

Boehringer Ingelheim has initiated a Phase IIa clinical trial of BI 765423, a novel IL-11–targeting monoclonal antibody, in patients with Idiopathic Pulmonary Fibrosis (IPF), advancing its efforts to develop new treatment options for progressive fibrotic lung diseases.

Boehringer Ingelheim | 15/01/2026 | By News Bureau |  127

Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class CKD Treatments

The collaboration will focus on accelerating the development of first-in-class oral small-molecule therapies for chronic kidney disease and other conditions, leveraging Rectify’s ABCC6-targeting platform designed to reduce pathological calcification.

Boehringer Ingelheim | 23/12/2025 | By News Bureau

Sanofi and Novartis Reach Separate Agreements with US Government to Lower Drug Prices and Support Innovation

Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.

Boehringer Ingelheim | 22/12/2025 | By News Bureau |  137

Takeda Becomes a BaseLaunch Partner

BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.

Boehringer Ingelheim | 19/12/2025 | By News Bureau

Lung Cancer Canada and Boehringer Ingelheim Canada Partner to Advance NSCLC Diagnostics

Lung Cancer Canada and Boehringer Ingelheim have launched a two-stage initiative to accelerate innovation in NSCLC diagnostics. The effort begins with a national Diagnostic Innovation Lab to identify key barriers in diagnosis, followed by an innovation challenge seeking solutions to close those gaps.

Boehringer Ingelheim | 29/11/2025 | By Dineshwori |  105

Boehringer Ingelheim Acquires Licence from Kyowa Kirin to Develop Treatment for Autoimmune Diseases

Boehringer Ingelheim has acquired a licence from Kyowa Kirin to develop a small molecule programme targeting autoimmune diseases. The collaboration aims to address significant unmet medical needs and strengthen Boehringer’s pipeline of innovative therapies for patients with inflammatory and immune-related conditions.

Boehringer Ingelheim | 31/10/2025 | By Dineshwori |  175

Boehringer Ingelheim's Zongertinib Shows 77 Percent Response Rate in HER2-Mutant NSCLC

Boehringer Ingelheim presented Phase Ib Beamion LUNG-1 trial data at ESMO 2025, showing that zongertinib achieved a 77 percent Objective Response Rate (ORR) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC.

Boehringer Ingelheim | 24/10/2025 | By Dineshwori |  218